News

The product line includes radiation sources and standards used in a variety of areas for calibration, measurement, analysis and control. The transaction is valued at approximately $6 million

This Phase I trial will assess the safety and pharmacokinetic profile of CVT-3619 in healthy volunteers. The Phase I program will provide early data on the compound’s potential

The Phase II clinical trial of FX06 (Fire study) in 234 patients with acute myocardial infarcts was completed in March 2008, with data indicating a statistically significant reduction

Mr Ueda will be responsible for licensing and commercialization activities in the Asia-Pacific area, including Japan. Mr Ueda graduated from the School of Pharmaceutical Sciences, Kyoto University. Mr

Cytovance Biologics has completed the process transfer and scale-up to 100L of a fed-batch bioreactor production process using Invitrogen’s new CD OptiCHO medium and CHO CD EfficientFeed supplement

Mr Tanaka is newly retired from Biosense Webster, a Johnson & Johnson company, where he most recently served as worldwide president. Mr Tanaka has received a bachelor of

In addition to his financial responsibilities, Mr Jacobson will be accountable for Ricerca’s legal, human resources, facilities and IT functions. Prior to joining Ricerca, Mr Jacobson was the

As part of the overall understanding between the parties, Antares will be responsible for development and commercial manufacturing of the product and Dr Reddy’s will be responsible for

Discovered by Osi’s diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies. PSN821 is said to be